The information provided herein is accurate, updated and complete as per the best practices of the Company. Please note that this information should not be treated as a replacement for physical medical consultation or advice. We do not guarantee the accuracy and the completeness of the information so provided. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company. We do not take any responsibility for the consequences arising out of the aforementioned information and strongly recommend you for a physical consultation in case of any queries or doubts.
Gadoscan
12-24 Hours
ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Indicated for intravenous use in MRI to visualize lesions with abnormal vascularity (or those thought to cause abnormalities in the blood-brain barrier) in the brain (intracranial lesions), spine, and associated tissues
Adult Dose
Adults: The recommended dose is 0.2 mL/kg (0.1 mmol/kg) administered as a bolus intravenous injection.
Child Dose
Pediatric Patients (2-16 years): The recommended dose is 0.2 mL/kg (0.1 mmol/kg) administered as a bolus intravenous injection.
Contraindication
Chronic, severe kidney disease (glomerular filtration rate, GFR < 30 mL/min/1.73m²), or acute kidney injury prior hypersensitivity reaction
Precaution
Gadolinium-based contrast agents (GBCAs) increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs. Avoid use of GBCAs among these patients unless the diagnostic information is essential and not available with non-contrast enhanced MRI or other modalities.
The GBCA-associated NSF risk appears highest for patients with chronic, severe kidney disease (GFR < 30 mL/min/1.73m²) as well as patients with acute kidney injury.
Screen patients for acute kidney injury and other conditions that may reduce renal function.
